Sufentanil/triazolam sublingual - AcelRx

Drug Profile

Sufentanil/triazolam sublingual - AcelRx

Alternative Names: ARX-03; ARX-F03; sublingual sufentanil/triazolam NanoTab™; triazolam/sufentanil

Latest Information Update: 27 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AcelRx Pharmaceuticals
  • Class Benzodiazepines; General anaesthetics; Hypnosedatives; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action GABA A receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pain; Sedation

Highest Development Phases

  • Suspended Procedural pain; Sedation

Most Recent Events

  • 30 Jun 2011 Phase II development was completed in USA prior to June 2011
  • 22 Oct 2009 Final efficacy data from a phase II trial in Sedation and Procedural pain released by AcelRx Therapeutics
  • 01 Jun 2009 AcelRx Pharmaceuticals completes a phase II trial in Procedural pain and sedation in USA (NCT00894699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top